XOMA Royalty Corp
XOMADelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000791908
XOMA Royalty Corp was delisted in 2026; its insiders filed their last Form 4 on Jul 16, 2026; 98 institutions reported holding it in 13F filings for Q2 2026, worth $723.7M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by XOMA Royalty Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for XOMA Royalty Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Biotechnology Value Fund L P | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| BVF Partners L P | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| BVF Inc | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| Biotechnology Value Fund II LP | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| Lampert Mark N | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 0Indirect | Jul 16, 2026 | 2 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 0Indirect | Jul 16, 2026 | 2 |
| BVF I GP LLC | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| BVF II GP LLC | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| BVF GP Holdings LLC | 10% Owner | 0Indirect | Jul 16, 2026 | 2 |
| Montano Maricel Perea | Chief Legal Officer | 0Indirect | Jul 14, 2026 | 3 |
| Limber Joseph M | Director | 0 | Jul 14, 2026 | 3 |
| Kosacz Barbara | Director | 0 | Jul 14, 2026 | 2 |
| Wyszomierski Jack L | Director | 0 | Jul 14, 2026 | 3 |
| Hughes Owen | Chief Executive Officer | 0 | Jul 14, 2026 | 4 |
| Hernday Natasha | Director | 0 | Jul 14, 2026 | 2 |
| Sitko Bradley | Chief Investment Officer | 0Indirect | Jul 14, 2026 | 3 |
| Perry Matthew D | Director | 0 | Jul 14, 2026 | 2 |
| Trigilio Jeffrey | Chief Financial Officer | 0 | Jul 14, 2026 | 5 |
| Franklin Heather L | Director | 0 | Jul 14, 2026 | 2 |
| Burns Thomas M. | SVP, Finance & CFO | 30,079 | Sep 23, 2025 | 0 |
| Neal James R | CEO | 11,822 | Jul 18, 2022 | 0 |
| Van Ness W Denman | Director | – | May 20, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 (view filing) | Dec 4 | 4 days | Hughes OwenChief Executive Officer | PPurchaseDepositary Shares - 8.375% B Cumulative Stock | +100.0K | $25.05 | +$2.50M | +5,000.0%102.0K after | |
| Sep 23, 2025 (view filing) | Sep 22 | 1 day | Burns Thomas M.SVP, Finance & CFO | SSale | −4.33K | $35.99 | −$155.8K | −12.6%30.1K after | 3 lots |
| Jul 2, 2025 (view filing) | Jun 30 | 2 days | Sitko BradleyChief Investment Officer | PPurchaseDepositary Shares - 8.375% Series B Cumulative Stock | +2.00K | $25.39 | +$50.8K | +39.6%7.04K after | |
| May 21, 2025 (view filing) | May 20 | 1 day | Hughes OwenChief Executive Officer | SSale | −25.6K | $25.38 | −$650.7K | −29.0%62.7K after | |
| May 21, 2025 (view filing) | May 20 | 1 day | Burns Thomas M.SVP, Finance & CFO | SSale | −10.5K | $25.38 | −$266.0K | −31.7%22.6K after | |
| May 20, 2025 (view filing)6:56 PM ET | May 16 | 4 days | Biotechnology Value Fund L P and 9 others10% Owner | SSaleCommon Stock, $0.0075 par value per share | −392.7K | $27.10 | −$10.6M | −23.7%1.27M after | 2 lots |
| Apr 9, 2025 (view filing) | Apr 7 | 2 days | Sitko BradleyChief Investment Officer | PPurchaseDepositary Shares - 8.375% Series B Cumulative Stock | +2.00K | $24.70 | +$49.4K | +65.7%5.04K after | |
| Apr 7, 2025 (view filing) | Apr 3-4 | 4 days | Limber Joseph MDirector | PPurchaseDepositary Shares - 8.375% Series B Cumulative Stock | +20.0K | $25.23 | +$504.5K | New position20.0K after | 2 lots |
| Apr 7, 2025 (view filing) | Apr 3-7 | 4 days | Limber Joseph MDirector | PPurchase8.625% Series A Cumulative Perpetual Preferred Stock | +10.0K | $25.56 | +$255.6K | New position10.0K after | 3 lots |
| Apr 2, 2025 (view filing) | Mar 31 | 2 days | Sitko BradleyChief Investment Officer | PPurchase | +1.00K | $19.98 | +$20.0K | +9.5%11.5K after | |
| Apr 2, 2025 (view filing) | Mar 31 | 2 days | Sitko BradleyChief Investment Officer | PPurchaseDepositary Shares - 8.375% Series B Perpetual Preferred | +245 | $25.39 | +$6.22K | +8.8%3.04K after | |
| Apr 2, 2025 (view filing) | Apr 1 | 1 day | Burns Thomas M.SVP, Finance & CFO | PPurchaseDepositary Shares - 8.375% B Cumulative Stock | +1.00K | $25.46 | +$25.5K | +100.0%2.00K after | |
| Mar 25, 2025 (view filing) | Mar 21 | 4 days | Sitko BradleyChief Investment Officer | PPurchase | +1.33K | $20.65 | +$27.5K | +14.6%10.5K after | |
| Mar 25, 2025 (view filing) | Mar 21 | 4 days | Sitko BradleyChief Investment Officer | PPurchaseDepositary Shares - 8.375% B Cumulative Stock | +2.80K | $25.43 | +$71.2K | New position2.80K after | |
| Jan 28, 2025 (view filing)5:23 PM ET | Jan 24 | 4 days | Biotechnology Value Fund L P and 9 others10% Owner | SSaleCommon Stock, $0.0075 par value per share | −500.7K | $26.10 | −$13.1M | −100.0%0 after | 3 lots |
| Jan 28, 2025 (view filing)5:23 PM ET | Jan 24 | 4 days | Biotechnology Value Fund L P and 9 others10% Owner | SSaleCommon Stock, $0.0075 par value per share | −150.0K | $26.10 | −$3.91M | −100.0%0 after | |
| Jan 10, 2025 (view filing) | Jan 8 | 2 days | Sitko BradleyChief Investment Officer | PPurchase8.625% Series A Cumulative Perpetual Preferred Stock | +313 | $25.60 | +$8.01K | New position313 after | |
| Jan 10, 2025 (view filing) | Jan 8 | 2 days | Sitko BradleyChief Investment Officer | PPurchase8.625% Series A Cumulative Perpetual Preferred Stock | +82 | $25.60 | +$2.10K | New position82 after | |
| Jan 10, 2025 (view filing) | Jan 8 | 2 days | Sitko BradleyChief Investment Officer | PPurchase | +150 | $25.75 | +$3.86K | New position75 after | 2 lots |
| Jan 3, 2025 (view filing) | Dec 31, 2024 | 3 days | Sitko BradleyChief Investment Officer | PPurchase | +300 | $25.90 | +$7.77K | +3.4%9.15K after | |
| Nov 13, 2024 (view filing) | Nov 13 | Same day | Burns Thomas M.SVP, Finance & CFO | SSale | −9.78K | $29.94 | −$292.7K | −40.2%14.6K after | |
| Nov 13, 2024 (view filing) | Nov 13 | Same day | Hughes OwenChief Executive Officer | SSale | −21.9K | $29.95 | −$655.3K | −38.5%35.0K after | |
| Oct 4, 2023 (view filing) | Oct 2 | 2 days | Hughes OwenExec Chairman and Interim CEO | PPurchase | +1.00K | $13.83 | +$13.8K | +40.0%3.50K after | |
| Oct 4, 2023 (view filing) | Oct 2-3 | 2 days | Sitko BradleyChief Investment Officer | PPurchase | +1.75K | $14.20 | +$24.8K | +45.5%5.60K after | 2 lots |
| Sep 27, 2023 (view filing) | Sep 25-26 | 2 days | Hughes OwenExec Chairman and Interim CEO | PPurchase | +2.50K | $14.43 | +$36.1K | New position2.50K after | 2 lots |
| Jun 2, 2023 (view filing) | May 31 | 2 days | Sitko BradleyChief Investment Officer | PPurchase | +1.50K | $17.13 | +$25.7K | +75.0%3.50K after | 2 lots |
| May 25, 2023 (view filing) | May 23 | 2 days | Sitko BradleyChief Investment Officer | PPurchase | +850 | $19.00 | +$16.1K | +28.3%3.85K after | |
| May 25, 2023 (view filing) | May 23-24 | 2 days | Hughes OwenInterim CEO | PPurchaseDepositary Shares - 8.375% B Cumulative Stock | +2.00K | $23.63 | +$47.3K | New position2.00K after | 3 lots |
| May 22, 2023 (view filing) | May 19 | 3 days | Sitko BradleyChief Investment Officer | PPurchase | +1.00K | $19.50 | +$19.5K | +50.0%3.00K after | |
| May 17, 2023 (view filing) | May 16 | 1 day | Sitko BradleyChief Investment Officer | PPurchaseDepositary Shares - 8.375% B Cumulative Stock | +500 | $23.20 | +$11.6K | +33.3%2.00K after | 3 lots |
| May 16, 2023 (view filing) | May 12 | 4 days | Sitko BradleyChief Investment Officer | PPurchase | +2.00K | $18.99 | +$38.0K | New position2.00K after | 2 lots |
| May 16, 2023 (view filing) | May 15 | 1 day | Sitko BradleyChief Investment Officer | PPurchaseDepositary Shares - 8.375% B Cumulative Stock | +1.50K | $23.40 | +$35.1K | New position1.50K after | |
| Jan 9, 2023 (view filing)5:44 PM ET | Jan 5-6 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.0075 par value per share | +22.2K | $18.91 | +$420.7K | +1.4%1.62M after | 4 lots |
| Sep 27, 2022 (view filing)7:22 PM ET | Sep 23-27 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.0075 par value per share | +24.6K | $16.61 | +$409.3K | +1.6%1.60M after | 6 lots |
| Sep 16, 2022 (view filing)6:30 PM ET | Sep 14-16 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.0075 par value per share | +56.3K | $17.59 | +$990.7K | +3.3%1.77M after | 4 lots |
| Jul 18, 2022 (view filing) | Jul 15 | 3 days | Burns Thomas M.SVP, Finance & CFO | SSale | −2.00K | $31.66 | −$63.3K | −23.4%6.55K after | |
| Jul 18, 2022 (view filing) | Jul 15 | 3 days | Neal James RCEO | SSale | −25.0K | $29.84 | −$746.1K | −67.9%11.8K after | 3 lots |
| Mar 23, 2022 (view filing) | Mar 21-23 | 2 days | Neal James RCEO | SSale | −53.5K | $29.08 | −$1.55M | −81.9%11.8K after | 3 lots |
| Mar 23, 2022 (view filing) | Mar 21-23 | 2 days | Burns Thomas M.SVP, Finance & CFO | SSale | −14.5K | $29.18 | −$423.2K | −68.9%6.55K after | 3 lots |